zanubrutinib,ibrutinib,futibatinib,zilovertamab
merck,otsuka,janssen,beigene,oncternal therapeutics,abbvie
['mantle,(-dismantle)', 'alpine', 'zilovertamab', 'cll', ' ibru', ' futi', 'zilo-301', 'zanubrutinib', 'lymphoma', 'lymsm']
particularly impressive results for zilovertamab + ibrutinib in chronic lymphocytic leukaemia (cll), especially in patients with tp53 mutations, who had a pfs of 100% at median follow up of 42 months #lymsm #ash22 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer